AstraZeneca reports powerful COVID-19 protection in new vaccine trial

Share

Although AstraZeneca's vaccine has been authorized in more than 50 countries, it has not yet been given the green light in the U.S. The U.S. study comprised more than 30,000 volunteers, of whom two-thirds were given the vaccine while the rest got dummy shots.

The Covid-19 vaccine developed by Oxford University and AstraZeneca has been found 79 percent effective in preventing symptomatic illness in a large trial in the United States, Chile and Peru, the company said, paving the way for it to apply for USA approval.

Both individual's conditions improved, KDCA added.

Some industry analysts had soured on the AstraZeneca vaccine, concerned that the blood clot fears, even if unwarranted, could undermine confidence.

Approximately one-fifth of the volunteers from this most recent trial were over 65 and showed that after two doses, they were as protected against COVID-19 as the younger volunteers. An investigation is continuing for the other patient, who is now in good condition.

Fewer than 200,000 people in South Africa have been vaccinated against Covid-19 so far, but the country's health ministry confirmed on Sunday that its reserves of one million doses of the AstraZeneca vaccine are to leave the country.

AstraZeneca said its experts did not find any safety concerns. The majority of people in Germany, France, Italy and Spain now see the vaccine as unsafe, a survey by YouGov published by The Telegraph on Monday shows.

Germany, France and Italy seem to support the view taken by Von der Leyen, but questions remain as to why the European Union was slower than the United Kingdom and U.S.in backing vaccines and buying large quantities of them before their approval. A total of 9,703 adverse reactions after receiving a Covid-19 vaccine have been reported as of Monday - 9,592 had common symptoms, 89 had suspected anaphylaxis, six had severe reactions and 16 were deaths.

China says it will discuss climate, other issues with US
Kissinger spoke to the China Development Forum via a video that was recorded before this week's U.S. I think history and the global community will come to their own conclusions, Yang said.

But the AstraZeneca vaccine, which is already widely used outside the U.S., is seen as crucial to tackling the spread of Covid-19 across the globe because it is easier and cheaper to transport than rival shots. Unlike vaccines from Pfizer Inc. and partner BioNTech SE, and Moderna Inc., which have to be kept frozen, the Astra shot can be held at fridge temperature.

The AstraZeneca vaccine is what scientists call a "viral vector" vaccine.

There has been heightened concern after the Oxford-AstraZeneca vaccine roll-out was temporarily suspended in Europe in countries including Norway, France and Denmark because of reports of blood clotting.

An emergency investigation by the European Medicines Agency (EMA) came to the conclusion last Thursday that the vaccine is "safe and effective" in preventing coronavirus and "not associated with an increase in the overall risk of thromboembolic events, or blood clots".

While the European Union drug regulator backed the vaccine last week, and US trial results published Monday said there were no safety concerns, public trust in the shot has plummeted in Europe.

Drug-maker AstraZeneca said Monday its vaccine provided strong protection against COVID-19.

The company said it would "prepare for the primary analysis to be submitted to the [FDA] for Emergency Use Authorization in the coming weeks", and also promised to seek publication in a peer-reviewed journal. Previous trials have shown that an extended interval of up to 12 weeks demonstrated greater efficacy, which was also supported by immunogenicity data. It was initially considered a global leader in the race to field a vaccine against COVID-19.

Share